Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

March 14, 2026 by InsiderTrades.com

Key Points

Christopher Mutz sold 3,162 ANI Pharmaceuticals shares at an average price of $71.64 for a total of $226,525.68, reducing his holding to 91,309 shares (a 3.35% cut).
Multiple insiders (including Meredith Cook and Thomas Rowland) also disclosed open‑market sales this week, which coincided with the stock trading down about 2.8% and likely contributed to downward pressure on the share price.
Despite the insider selling, analysts remain largely positive—MarketBeat shows a consensus rating of “Moderate Buy” with an average price target of about $107.33 (roughly a 44% upside from the current ~$70 range).

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the business's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $72.62, for a total transaction of $36,310.00. Following the transaction, the vice president directly owned 79,390 shares in the company, valued at $5,765,301.80. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

On Tuesday, January 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $84.33, for a total transaction of $42,165.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $70.49 on Friday. ANI Pharmaceuticals, Inc. has a 52 week low of $56.71 and a 52 week high of $99.50. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 20.98 and a beta of 0.52. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71. The business's 50-day simple moving average is $79.12 and its 200-day simple moving average is $85.35.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

Positive Sentiment: Zacks/analyst bullishness — A Zacks piece highlights ANIP among four biotech names to watch for upside in 2026, citing new drug approvals and pipeline progress. Another Zacks story notes the consensus of Wall Street analysts implies roughly a 44.8% upside in ANIP, which could support buying interest if fundamentals continue to improve. 4 Biotech Stocks to Watch for Potential Upside in 2026 Analysts See a 44.84% Upside in ANI (ANIP)
Neutral Sentiment: Analyst/market coverage piece — Yahoo published a “sizing up” note after a recent share-price pullback that reviews valuation and technicals; such coverage can attract traders looking to buy a dip but doesn't itself guarantee direction. Sizing Up ANI Pharmaceuticals After Recent Share Price Pullback
Neutral Sentiment: Short interest data appears non‑informative — a March note shows effectively zero reported short interest (and a 0.0 days-to-cover), suggesting short activity is not currently driving the move. This item is ambiguous given the odd/empty figures provided.
Negative Sentiment: Insider selling — Several insiders disclosed open-market sales this week: VP Meredith Cook sold 500 shares (avg ~$72.62; SEC filing), insider Christopher Mutz sold 3,162 shares (avg ~$71.64; SEC filing), and SVP Thomas Rowland sold 4,772 shares (avg ~$74.91; SEC filing). Combined, these disclosures show executives trimming positions and likely contributed to downward pressure on the stock today. Meredith Cook Form 4 Christopher Mutz Form 4 Thomas Rowland Form 4

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 6th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 price objective on the stock. Weiss Ratings restated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Finally, Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $107.33.

Get Our Latest Analysis on ANI Pharmaceuticals

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANIP. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 9.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company's stock worth $138,000 after purchasing an additional 126 shares during the period. Maryland State Retirement & Pension System raised its stake in shares of ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company's stock valued at $206,000 after purchasing an additional 134 shares during the period. Illinois Municipal Retirement Fund lifted its holdings in shares of ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company's stock valued at $782,000 after purchasing an additional 145 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of ANI Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company's stock valued at $464,000 after purchasing an additional 154 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company's stock worth $1,267,000 after buying an additional 198 shares during the period. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.